达比加群治疗非瓣膜性房颤患者大出血事件的管理:一项回顾性多中心综述
该回顾性多中心观察性图表综述纳入191例因急性大出血就诊于急诊的达比加群治疗非瓣膜性房颤患者,检索电子病历数据库交叉核对药物列表与出血ICD-9/ICD-10编码,纳入确认非瓣膜性房颤且大出血索引事件前5天内至少使用1剂达比加群者。结果显示62%为胃肠道出血,19%为颅内出血(其中4%非创伤性、15%创伤性),19%位于其他部位,0.5%部位未知;死亡12例(6%)。尽管红细胞和血浆输注常见,仅11例(6%)接受纯化凝血因子。作者结论认为,尽管逆转策略使用罕见,该样本死亡率低且结局良好,与临床试验报告结局相似。
要点
- 191例达比加群相关大出血患者中,胃肠道出血118例(62%),颅内出血36例(19%,非创伤性8例占4%、创伤性28例占15%)。
- 总体死亡12例(6%):胃肠道出血8例、非创伤性颅内出血2例、其他部位2例。
- 仅11例(6%)接受纯化凝血因子,红细胞和血浆输注常见但原文未报告具体比例。
- 作者结论认为尽管逆转策略使用罕见,死亡率低且结局与临床试验相似。
适用人群与场景
- 达比加群治疗的非瓣膜性房颤患者,因急性大出血就诊于急诊。
- 纳入条件:确认非瓣膜性房颤,大出血索引事件前5天内至少使用1剂达比加群。
研究设计与关键结果
- 研究类型:回顾性观察性图表综述,多中心;电子检索得284例,排除93例不合格,最终队列191例。
- 出血部位:胃肠道出血118例(62%);颅内出血36例(19%),其中非创伤性8例(4%)、创伤性28例(15%);其他部位36例(19%);未知1例(0.5%)。
- 死亡:12例(6%),其中胃肠道出血8例、颅内出血2例(均为非创伤性)、其他部位2例。
- 治疗:红细胞和血浆输注常见(原文未报告具体比例);仅11例(6%)接受纯化凝血因子。
证据类型、等级与局限
- 证据类型:回顾性观察性图表综述(多中心)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,尽管逆转策略使用罕见,该样本死亡率低且结局良好,与临床试验报告结局相似。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
STUDY OBJECTIVE: There are limited data on the clinical presentations and management of dabigatran-associated major bleeding outside the clinical trial setting. The aim of this study is to describe clinical characteristics, interventions, and outcomes in patients with dabigatran-associated major bleeding who present to the emergency department (ED).
METHODS: We performed a retrospective observational chart review study of dabigatran-treated patients with nonvalvular atrial fibrillation who presented with acute major bleeding to the ED. We searched electronic medical record databases cross-referencing medication lists and hemorrhage International Classification of Diseases, Ninth Revision (ICD-9) and ICD-10 codes. We studied the resulting charts to yield confirmed nonvalvular atrial fibrillation in patients with an index event of major bleeding and at least 1 dose of dabigatran in the 5 preceding days.
RESULTS: The electronic search yielded 284 cases, and we assessed 93 as ineligible, leaving 191 in the final cohort. Of these, 118 patients (62%) had gastrointestinal hemorrhage; 36 (19%) had intracranial hemorrhage, 8 (4%) of which were nontraumatic cases and 28 (15%) traumatic. Thirty-six (19%) of the index events were in "other" locations and 1 (0.5%) "unknown." There were 12 deaths (6%): 8 from patients presenting with gastrointestinal bleeding events, 2 from intracranial hemorrhage (both nontraumatic), and 2 from other. Although RBC and plasma transfusions were common, only 11 patients (6%) received purified coagulation factors.
CONCLUSION: Despite rare use of reversal strategies, mortality was low and outcomes were favorable, similar to reported outcomes from clinical trials, in this sample of patients with major bleeding while receiving dabigatran.
参考来源
- Milling TJ, Fromm C, Ganetsky M, et al. Management of Major Bleeding Events in Patients Treated With Dabigatran for Nonvalvular Atrial Fibrillation: A Retrospective, Multicenter Review. Ann Emerg Med. 2017. PMID: 28196608. doi:10.1016/j.annemergmed.2016.11.040
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。